Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.
Fiche publication
Date publication
novembre 2015
Journal
The Lancet. Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi
Tous les auteurs :
Tournigand C, Chibaudel B, Samson B, Scheithauer W, Vernerey D, Mésange P, Lledo G, Viret F, Ramée JF, Tubiana-Mathieu N, Dauba J, Dupuis O, Rinaldi Y, Mabro M, Aucoin N, Latreille J, Bonnetain F, Louvet C, Larsen AK, André T, de Gramont A
Lien Pubmed
Résumé
The combination of an anti-VEGF or an anti-EGFR-targeted monoclonal antibody with chemotherapy has shown clinical activity in patients with metastatic colorectal cancer. However, combining both anti-VEGF and anti-EGFR antibodies with chemotherapy in first-line treatment resulted in adverse outcomes. We assessed whether the combination of erlotinib, an EGFR tyrosine kinase inhibitor, with bevacizumab could increase the efficacy of maintenance therapy in patients with unresectable metastatic colorectal cancer.
Mots clés
Aged, Angiogenesis Inhibitors, administration & dosage, Antineoplastic Agents, administration & dosage, Bevacizumab, administration & dosage, Colorectal Neoplasms, drug therapy, Disease-Free Survival, Drug Therapy, Combination, Erlotinib Hydrochloride, administration & dosage, Female, Humans, Maintenance Chemotherapy, Male, Middle Aged
Référence
Lancet Oncol.. 2015 Nov;16(15):1493-1505